Two years ago, Emma Dimery faced a devastating diagnosis: stage 4 colon cancer, deemed incurable. Today, she is healthy and cancer-free—thanks to a last-resort clinical trial that may be redefining cancer treatment.

At just 23 years old, Dimery, a Minnesota resident, began experiencing abdominal pain and abnormal bloodwork. A colonoscopy revealed two tumors—one softball-sized, the other golf ball-sized. Despite undergoing multiple surgeries, chemotherapy, radiation, and combination therapies, her treatment-resistant cancer continued to spread.

“I was basically treading water,” Dimery shared. For years, she endured bi-weekly immunotherapy, hoping for a breakthrough. “I had exhausted every standard—and even some non-standard—treatments.”

That breakthrough came with a clinical trial at the University of Minnesota, led by Dr. Emil Lou, a medical oncologist and research scientist. The trial tested an experimental genetic therapy described as the next frontier of immunotherapy.

Unlike traditional immunotherapies that target the outside of cancer cells, this therapy focused on intracellular targets—structures inside the cancer cells that suppress the immune system's response. Using CRISPR-Cas9 gene editing technology, often called “genetic scissors,” researchers modified cancer cells in the lab to enhance the body’s ability to recognize and destroy tumors.

These engineered cells were then infused back into patients. In Dimery’s case, the results were astonishing. After just one infusion, she was declared cancer-free—a response that Dr. Lou called “remarkable” and “almost unheard-of” for metastatic colorectal cancer.

“This is what we call a clinical complete response,” Lou explained, noting that such outcomes occur in less than 10% of advanced colorectal cancer cases.

Dimery, now 35, has remained cancer-free for over two years. While she hesitates to use the word “cure,” she acknowledges the transformation: “Until now, the best I could hope for was remission. But now, I feel like I’m living again.”

Her case was presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, sparking hope among researchers. “Emma is exceptional,” said Lou, “but the goal is to replicate her results in more patients.”

The story also sheds light on the surge in early-onset colon cancer. In 2023, 1 in 10 colorectal cancer diagnoses were in patients under 50. Experts predict these numbers will double by 2030.

Despite having effective screening tools like blood tests, stool tests, and colonoscopies, many young people remain undiagnosed until late-stage. “It’s alarming how often we see stage 4 cases in people with few or no symptoms,” Lou said.

Dimery emphasized the importance of awareness, genetic testing, and clinical trial access: “It’s so important to stay informed. I had the right kind of cancer for this treatment. Others might, too.”